EDIT · Editas Medicine, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on EDIT. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About EDIT · Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Live Quote
HOLD (score +2) · 12-1 mom 18.7% · RSI 50.2 · above_200_only · -33.5% from high
Targets blend Wall Street consensus (9 analysts: low $1.00 / mean $5.78 / high $15.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Stage crashed before producing an artifact (e.g. LM Studio timeout, malformed JSON, network error). The cooldown will hold this off the queue for ~1h before retry.
The investigation into Editas Medicine reveals that the Form 4 cluster trigger was not genuine open-market insider buying but rather mandatory tax-withholding sales from RSU vestings under pre-set 10b5-1 plans by three insiders (CEO, CFO, CSO) on June 3. These are NOT bullish signals. EDIT is a loss-making preclinical gene-editing biotech with ~$124M cash and an accumulated deficit of $1.65B burning roughly $23M/quarter in Q1 2026. The company raised $117M gross via a dilutive secondary offering (55.5M shares + warrants) on May 26, 2026. EDIT-401 shows strong (~90%) LDL-C/Lp(a)/ApoB reductions in NHPs with CTN filing targeted mid-2026 and early human proof-of-concept by end of 2026 — but this is entirely preclinical with no guarantee of clinical success. The stock has collapsed ~45% from its 52-week high, sits below both MAs, shows bearish technical momentum (RSI 40.9, MACD bearish cross). No credible mispricing edge exists given the binary risk profile and near-certain future dilution.
Anti-signal gates (going_concern, dilution, accounting) are active and valid. EDIT's stockholders' equity collapsed to $4.4M with a $1.65B accumulated deficit, creating severe financial distress despite the recent offering. The dossier confirms no edge over the market, and the binary clinical risk combined with structural overhang precludes a viable long or income setup.
EDIT is a cash-burning pre-clinical gene editing company that has raised ~$117M in a May 2026 equity offering (55.5M shares + warrants) days before this investigation was triggered. The Form 4 cluster — the stated trigger — consisted entirely of pre-arranged tax-withholding sales by three insiders (CEO, CFO, CSO), not open-market purchases. There are no genuine insider open-market buys in any recent window. EDIT-401 for hyperlipidemia is on track to file an IND mid-2026 with early human proof-of-concept data expected year-end 2026 — a real catalyst — but the stock is now heavily diluted post-offering and sitting near its post-offering low ($2.71 from ~$3.08 offer price). The options flow shows strong call-bias (95.6% net directional), but at micro-cap scale this reflects speculative interest, not institutional conviction. No asymmetric long setup exists given heavy dilution and the distance between current price ($2.71) and analyst target mean ($5.78). This warrants income-only consideration.
Editas is a pre-revenue CRISPR gene editing biotech that just completed a massive $319M public offering (55.5M new shares + warrants) in the same week it announced positive EDIT-401 preclinical data at EAS Congress showing ~90% LDL-C/Lp(a)/ApoB reductions in NHPs. The company is burning ~$23M/quarter with only $123M in cash, and the dilution — on top of prior ATM sales totaling 14.3M shares for $43.9M — massively expands the share count at a time when no product revenue exists. EDIT-401 remains preclinical with a CTN filing planned mid-2026; human proof-of-concept is 12+ months away. No insider open-market buys in 90 days, only option grants (CEO: 1.015M shares; CFO: 292K shares) as part of compensation packages. The stock is technically neutral to bearish with no smart-money clustering signal.
Editas Medicine is a pre-revenue CRISPR gene editing biotech whose lead program EDIT-401 showed compelling preclinical data (90%+ LDL-C reduction in NHPs at 6 months) presented at ASGCT on May 14. The company switched auditors from EY to PwC in April and recently reported Q1 results with narrowing losses (-$0.26 vs -$0.24 est). However, the stock is deeply unprofitable (negative FCF), trading near cash ($123M net cash vs $256M market cap), below both 50DMA and 200DMA, and has a dangerous ~18-month runway into Q3 2027 — insufficient for Phase I/II completion. The CEO received a large options grant (1M shares at $2.54) in March but no open-market insider purchases exist. IV is elevated (~115% ATM on June expiry). No asymmetric long or income setup is compelling given the binary clinical risk and near-term cash constraints.